Nørregaard 1995.

Study characteristics
Methods	Design: parallel Duration: 8 weeks Assessment: baseline and post‐intervention Country: Denmark
Participants	Pain condition: fibromyalgia Population: people with fibromyalgia Minimum pain intensity: no Inclusion criteria Fulfilled the ACR criteria for fibromyalgia during the last year Exclusion criteria Severe physical and mental health comorbidities Total participants randomised: 43 Age in years (mean, SD): 49 Gender: NR Pain duration in years (mean, SD): NR
Interventions	Placebo n = 21 Inert Identical appearance and sham dosing Citalopram 20‐40 mg n = 21 SSRI Forced titration to fixed dose depending on response: started on 20 mg a day for 4 weeks (1 tablet), and then if participants did not report 2‐point improvement then they were upped to 40 mg (2 tablets)
Outcomes	Pain intensity Mood Physical function Sleep
Missing data methods	ITT but methods NR
Funding source	Pharmaceutical: "This work was supported by funding from H. Lundbeck A/S."
Conflicts of interest	NR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not specified
Allocation concealment (selection bias)	Unclear risk	Allocation procedures not specified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, identical study drugs with sham dosing
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	State ITT but no methods specified Attrition Total: 10/43 (23.3%) Attrition per arm NR
Selective reporting (reporting bias)	Unclear risk	No protocol or trial registration found
Other bias	Low risk	No other sources of bias were identified